| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA057-001 (SUCCESSOR-1) | 23-20 | Relapsed or refractory multiple myeloma |
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure. |
DSSG Group: Multiple Myeloma
Discontinuation Study
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Discontinuation Study | 20-28 | Multiple Myeloma in sustainable |
MajesTEC-4
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MajesTEC-4 | 23-21 | Newly diagnosed multiple myeloma |
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant. |
AFFIRM-AL
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Isa-RVD
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Isa-RVD | 19-34 | The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria. |
This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma |